FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Women with adverse pregnancy outcomes (APOs) have an increased risk for cardiovascular disease (CVD), as do their APO-free sisters.

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

A study has found that, in the United States, the rate of sudden cardiac death is increasing among adults aged 25 to 44 years.

Patients with pregnancy-related hypertension (HTN) or diabetes are more likely to be screened for diabetes and dyslipidemia after delivery.